These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 20960569)

  • 1. PCPP-formulated H5N1 influenza vaccine displays improved stability and dose-sparing effect in lethal challenge studies.
    Andrianov AK; Decollibus DP; Marin A; Webb A; Griffin Y; Webby RJ
    J Pharm Sci; 2011 Apr; 100(4):1436-43. PubMed ID: 20960569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine.
    Baras B; Stittelaar KJ; Simon JH; Thoolen RJ; Mossman SP; Pistoor FH; van Amerongen G; Wettendorff MA; Hanon E; Osterhaus AD
    PLoS One; 2008 Jan; 3(1):e1401. PubMed ID: 18167560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poly[di(carboxylatophenoxy)phosphazene] (PCPP) is a potent immunoadjuvant for an influenza vaccine.
    Payne LG; Jenkins SA; Woods AL; Grund EM; Geribo WE; Loebelenz JR; Andrianov AK; Roberts BE
    Vaccine; 1998 Jan; 16(1):92-8. PubMed ID: 9607015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pandemic H1N1 vaccine requires the use of an adjuvant to protect against challenge in naïve ferrets.
    Baras B; de Waal L; Stittelaar KJ; Jacob V; Giannini S; Kroeze EJ; van den Brand JM; van Amerongen G; Simon JH; Hanon E; Mossman SP; Osterhaus AD
    Vaccine; 2011 Mar; 29(11):2120-6. PubMed ID: 21238573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longevity of the protective immune response induced after vaccination with one or two doses of AS03A-adjuvanted split H5N1 vaccine in ferrets.
    Baras B; Stittelaar KJ; Kuiken T; Jacob V; Bernhard R; Giannini S; de Waal L; van Amerongen G; Simon JH; Osterhaus AD; Hanon E; Mossman SP
    Vaccine; 2011 Mar; 29(11):2092-9. PubMed ID: 21237275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections.
    Liu G; Song L; Reiserova L; Trivedi U; Li H; Liu X; Noah D; Hou F; Weaver B; Tussey L
    Vaccine; 2012 Nov; 30(48):6833-8. PubMed ID: 23000130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Superior protection provided by a single dose of MF59-adjuvanted whole inactivated H5N1 influenza vaccine in type 1 diabetic mice.
    Wu J; Wang F; Fang F; Zhang W; Chang H; Zheng L; Chen Z
    Arch Virol; 2011 Mar; 156(3):387-95. PubMed ID: 21110049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.
    Mahmood K; Bright RA; Mytle N; Carter DM; Crevar CJ; Achenbach JE; Heaton PM; Tumpey TM; Ross TM
    Vaccine; 2008 Oct; 26(42):5393-9. PubMed ID: 18706956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GLA-AF, an emulsion-free vaccine adjuvant for pandemic influenza.
    Clegg CH; Roque R; Perrone LA; Rininger JA; Bowen R; Reed SG
    PLoS One; 2014; 9(2):e88979. PubMed ID: 24551202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice.
    Harada Y; Ninomiya-Mori A; Takahashi Y; Shirakura M; Kishida N; Kageyama T; Tada Y; Tashiro M; Odagiri T
    Vaccine; 2011 Oct; 29(46):8330-7. PubMed ID: 21911027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.
    Keitel W; Groth N; Lattanzi M; Praus M; Hilbert AK; Borkowski A; Tsai TF
    Vaccine; 2010 Jan; 28(3):840-8. PubMed ID: 19835829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent adjuvant effects of novel NKT stimulatory glycolipids on hemagglutinin based DNA vaccine for H5N1 influenza virus.
    Hung JT; Tsai YC; Lin WD; Jan JT; Lin KH; Huang JR; Cheng JY; Chen MW; Wong CH; Yu AL
    Antiviral Res; 2014 Jul; 107():110-8. PubMed ID: 24786174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge.
    Govorkova EA; Webby RJ; Humberd J; Seiler JP; Webster RG
    J Infect Dis; 2006 Jul; 194(2):159-67. PubMed ID: 16779721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single dose of oil-adjuvanted inactivated vaccine protects chickens from lethal infections of highly pathogenic H5N1 influenza virus.
    Hwang SD; Kim HS; Cho SW; Seo SH
    Vaccine; 2011 Mar; 29(11):2178-86. PubMed ID: 21172378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of poly[di(sodium carboxylatophenoxy)phosphazene] (PCPP) as mucosal adjuvant to induce protective immunity against respiratory pathogens.
    Shim DH; Ko HJ; Volker G; Potter AA; Mutwiri G; Babiuk LA; Kweon MN
    Vaccine; 2010 Mar; 28(11):2311-7. PubMed ID: 20060944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ferrets and the challenges of H5N1 vaccine formulation.
    Hampson AW
    J Infect Dis; 2006 Jul; 194(2):143-5. PubMed ID: 16779718
    [No Abstract]   [Full Text] [Related]  

  • 18. Programming of Influenza Vaccine Broadness and Persistence by Mucoadhesive Polymer-Based Adjuvant Systems.
    Noh HJ; Chowdhury MY; Cho S; Kim JH; Park HS; Kim CJ; Poo H; Sung MH; Lee JS; Lim YT
    J Immunol; 2015 Sep; 195(5):2472-82. PubMed ID: 26216889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-clade protection against HPAI H5N1 influenza virus challenge in BALB/c mice intranasally administered adjuvant-combined influenza vaccine.
    Yang P; Tang C; Luo D; Zhan Z; Xing L; Duan Y; Jia W; Peng D; Liu X; Wang X
    Vet Microbiol; 2010 Nov; 146(1-2):17-23. PubMed ID: 20888151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model.
    Ninomiya A; Imai M; Tashiro M; Odagiri T
    Vaccine; 2007 May; 25(18):3554-60. PubMed ID: 17293015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.